Molecule
Satralizumab is a prescription medicine indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Satralizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for: the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients.
Source: US FDA prescribing information
The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD and TED is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.
Source: US FDA prescribing information
Hepatitis B virus, tuberculosis, and liver transaminase screening is required before the first dose. Prior to every use, determine if there is an active infection. The recommended loading dosage of ENSPRYNG is: NMOSD: for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks. TED: for body weight 40-100kg, for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks. For body weight >100 kg: for the first three administrations is 180 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 180 mg every 4 weeks. See Full Prescribing Information for important preparation and administration instructions.
Source: US FDA prescribing information
ENSPRYNG is contraindicated in patients with: A known hypersensitivity to satralizumab or any of the inactive ingredients Active Hepatitis B infection Active or untreated latent tuberculosis Known hypersensitivity to satralizumab or any of the inactive ingredients. Active Hepatitis B infection. Active or untreated latent tuberculosis
Source: US FDA prescribing information
Infections: Delay ENSPRYNG administration in patients with an active infection until the infection is resolved. Vaccination with live or live-attenuated vaccines is not recommended during treatment. Elevated Liver Enzymes: Monitor ALT and AST levels during treatment, interruption of ENSPRYNG may be required. Decreased Neutrophil Counts: Monitor neutrophils during treatment.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Infections Elevated Liver Enzymes Decreased Neutrophil Counts Hypersensitivity Reactions The most common adverse reactions in patients with NMOSD (incidence at least 15%) are nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, and nausea. The most common adverse reactions in patients with TED (incidence at least 5%) are upper respiratory tract infection, and alanine aminotransferase increased.
Source: US FDA prescribing information
Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. ENSPRYNG can be stored out of refrigeration for a maximum of 8 days at a temperature that does not exceed 30°C (86°F). If ENSPRYNG is removed from and returned to the refrigerator, the total combined time out of refrigeration should not exceed 8 days. Do not shake. Always keep in the original carton to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Satralizumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Enspryng 120 mg/1 mL injectionSubcutaneous Cold chain | Genentech | US FDA | Available on request |
| Enspryng 180 mg/1.5 mL injectionSubcutaneous Cold chain | Genentech | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Satralizumab in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Satralizumab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Satralizumab, including Enspryng.
Yes. The US FDA first approved Satralizumab on 14 August 2020, according to Drugs@FDA.
Yes. Satralizumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Satralizumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Satralizumab is classified under ATC code L04AC (Immunosuppressive drug, subgroup L04AC).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.